Invivyd, Inc. (NASDAQ:IVVD) Given Average Recommendation of “Hold” by Brokerages

Shares of Invivyd, Inc. (NASDAQ:IVVD) have received an average rating of “Hold” from the six research firms that are currently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $8.00.

Several research firms recently weighed in on IVVD. D. Boral Capital reaffirmed a “hold” rating on shares of Invivyd in a research report on Tuesday, November 25th. Zacks Research upgraded shares of Invivyd from a “strong sell” rating to a “hold” rating in a research report on Thursday, November 13th. BTIG Research reaffirmed a “buy” rating on shares of Invivyd in a report on Wednesday, January 21st. Weiss Ratings reiterated a “sell (e+)” rating on shares of Invivyd in a research report on Monday, December 29th. Finally, HC Wainwright boosted their price objective on shares of Invivyd from $5.00 to $10.00 and gave the company a “buy” rating in a research report on Friday, October 31st.

Insider Activity

In other Invivyd news, Director Kevin F. Mclaughlin purchased 50,000 shares of the stock in a transaction dated Wednesday, November 19th. The stock was bought at an average price of $2.50 per share, with a total value of $125,000.00. Following the acquisition, the director owned 50,000 shares of the company’s stock, valued at approximately $125,000. This represents a ? increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 25.40% of the company’s stock.

Institutional Trading of Invivyd

Several large investors have recently bought and sold shares of the business. Courier Capital LLC bought a new position in Invivyd in the fourth quarter valued at about $25,000. Bronte Capital Management Pty Ltd. acquired a new stake in shares of Invivyd in the 4th quarter valued at approximately $27,000. Catalyst Funds Management Pty Ltd bought a new stake in shares of Invivyd during the 2nd quarter valued at approximately $27,000. Vanguard Personalized Indexing Management LLC grew its holdings in shares of Invivyd by 238.6% during the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 39,941 shares of the company’s stock valued at $29,000 after purchasing an additional 28,146 shares during the last quarter. Finally, ProShare Advisors LLC acquired a new position in Invivyd during the 4th quarter worth approximately $30,000. 70.36% of the stock is owned by institutional investors and hedge funds.

Invivyd Price Performance

Shares of NASDAQ IVVD opened at $1.59 on Monday. The business has a fifty day moving average price of $2.31 and a two-hundred day moving average price of $1.71. The stock has a market capitalization of $370.66 million, a PE ratio of -3.38 and a beta of 0.60. Invivyd has a fifty-two week low of $0.46 and a fifty-two week high of $3.07.

Invivyd (NASDAQ:IVVD) last issued its quarterly earnings results on Thursday, November 6th. The company reported ($0.06) EPS for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.01). The company had revenue of $13.13 million during the quarter, compared to the consensus estimate of $12.00 million. Invivyd had a negative return on equity of 92.97% and a negative net margin of 119.63%. On average, equities analysts expect that Invivyd will post -1.64 EPS for the current year.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.